TNMplot: An enhanced platform for pharmacological target identification through cross-stage and pan-cancer gene...

Area of Science:

• Oncology
• Bioinformatics
• Genomics

Background:

• Large-scale transcriptomic data analysis is crucial for understanding cancer progression and identifying therapeutic targets.
• Existing platforms may lack integrated analysis of RNA-Seq and gene-chip data across multiple cancer types.

Purpose of the Study:

• To introduce an updated TNMplot platform with novel features for pharmacological and translational oncology research.
• To enhance transcriptomic profiling and facilitate biomarker discovery and preclinical target validation.

Main Methods:

• Integration of RNA-Seq and gene-chip data from 56,938 samples across 22 tumour types.
• Implementation of stage-based expression comparison for progression-related gene identification.
• Inclusion of enhanced visualization and multi-gene analytics tools.

Main Results:

• Identification of progression markers from 4470 cancer samples, including breast, colorectal, lung, skin, and prostate tumors.
• Enhanced visualization tools like pan-cancer dot matrix for multi-tissue and multi-gene comparison.
• New multi-gene analytics supporting investigation of druggable pathways and pharmacogenomic biomarkers.

Conclusions:

• The updated TNMplot platform provides a comprehensive environment for transcriptomic analysis in oncology.
• The platform supports pharmacological hypothesis generation, biomarker discovery, and preclinical target validation.
• Parallel analysis of RNA-Seq and gene chip datasets ensures robust cross-platform validation of potential drug targets.